Navigation Links
Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Date:12/11/2007

Three-fold Lower Incidence of Severe Cardiac Toxicity With Equivalent

Complete Remission Rates Reported

ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that preliminary data from its phase II/III randomized study comparing CPOP-R to CHOP-R in the first-line treatment of patients with aggressive non-Hodgkin's lymphoma (NHL) showed patients who received pixantrone experienced less severe (grade 3/4) toxicities including severe infection and febrile neutropenia when compared to patients treated with standard doxorubicin-based therapy. A preliminary analysis of the study, known as PIX203, which is ongoing, was presented at the American Society of Hematology (ASH) Annual Meeting in Atlanta.

"While preliminary, these randomized trial results are encouraging in supporting the preclinical findings that pixantrone is associated with a lower incidence of severe cardiac damage as evidenced by substantial declines in ejection fraction than standard anthracylines such as doxorubicin when administered as part of combination chemotherapy in the front line treatment of aggressive NHL," said Jack W. Singer, Chief Medical Officer of CTI. "Although preliminary, these data suggest that there may be reductions in other clinically important toxicities such as febrile neutropenia and severe infections without a loss in anti-tumor activity. These findings, along with its robust preclinical profile, suggest that pixantrone is an ideal drug candidate for further investigation in clinical trials for NHL, breast cancer and other diseases where anthracyclines are standard of care."

CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) Compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituximab) in 1st Line Therapy of Diffuse Large B cell Lymphoma (DLBCL): An Interim Analysis

Data were presented that show CPOP-R had comparable ant
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy versus Placebo for IBS Symptoms
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
8. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
11. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Lumin Medical LLC, a healthcare IT provider, ... leading provider of on-demand patient tracking solutions and is ... to Franklin, Wis. ... and our mission is to provide visibility for the ... reduce costs," said James Hermann , President of ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... EAGAN, Minn. , July 14, 2014  Today, ... Partners, announced that it acquired the assets of MicroTest ... MA.  The acquisition of MTL is the first step ... and chemistry laboratory services platform to support the medical ... be known as Accuratus Lab Services , a ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3
... III Study for the Treatment of Advanced Prostate CancerPARSIPPANY, ... launch of a Phase IIIB clinical trial of degarelix ... antagonist approved by the U.S. Food and Drug Administration ... cancer. The announcement was made at ...
... Diagnostic ToolSUNNYVALE, Calif., April 27 Cepheid (Nasdaq: ... MTB/RIF as a CE IVD Mark product under the ... Devices. For the first time, European clinicians will have ... Mycobacterium tuberculosis (MTB) and resistance to rifampicin ...
Cached Medicine Technology:Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6
(Date:7/14/2014)... Tysons, VA (PRWEB) July 14, 2014 ... been a local icon to the Tysons Corner skyline ... Corner becoming its own municipality, known simply as “Tysons”, ... Sheraton Tysons Hotel. In addition to Tysons becoming ... Stations located in the heart of Tysons brings an ...
(Date:7/14/2014)... TX (PRWEB) July 14, 2014 Kenn Renner ... recently. The video is meant to describe the business on ... estate broker and national speaker – Kenn Renner – is ... branding, marketing, and goal setting techniques. , Investing in real ... money. Some people do it as their career, while others ...
(Date:7/14/2014)... 2014 Dry eyes, contrary to popular opinion, ... recent research have pointed out, today’s technology has practically enabled ... as a result of using laptops and smartphones to ... Because of this phenomenon, it has become imperative for people ... cure them from having dry eyes, but prevent it from ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 The Cabin ... launched its new Alumni Community website – ... treatment, to help them maintain lifelong recovery wherever they ... that providing clients the tools to help them maintain ... and essential part of any reputable treatment programme. As ...
(Date:7/14/2014)... July 14, 2014 EurekaMag.com has newly ... which is a contagious liver disease that ranges ... weeks to a serious, lifelong illness that attacks the ... States have chronic Hepatitis C virus infection of which ... site's research category covers all studies on Hepatitis ...
Breaking Medicine News(10 mins):Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 2Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 3Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 4Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 2Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2
... off from certain osteoporosis drugs may be beneficial to bone ... System. Researchers found that bone density remained stable for three ... a popular class of osteoporosis drugs that can cause fractures ... bone. "These drugs are potentially harmful when taken for ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Nov. ... evidence that people infected with HIV, the virus that causes ... other patients when they undergo kidney transplants. Up until ... HIV patients because of fear that AIDS would quickly kill ...
... Johns Hopkins have identified a compound that could be ... The compound, called a glutaminase inhibitor, has been ... scientists say, may have the potential to be used ... Johns Hopkins scientists, are inventors on patent applications related ...
... NC Researchers have been stymied for years over the ... produce antibodies in response to the pathogen antibodies that ... at Duke University Medical Center can explain why: Some of ... can,t actually "see" the virus until after it,s already invaded ...
... THURSDAY, Nov. 18 (HealthDay News) -- Millions of harried ... indoor smoking at one in every four major U.S. ... smoke-free policies at large-hub airports in 2002 and 2010 ... nation,s largest airports, including three of the five busiest: ...
... Reinberg HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay ... example, new research finds that doctors, prescribing patterns vary across ... U.S. Food and Drug Administration. The result is ... depending on where they live, the researchers said. "We ...
Cached Medicine News:Health News:Taking a break from osteoporosis drugs can protect bones 2Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:Compound that blocks sugar pathway slows cancer cell growth 2Health News:Compound that blocks sugar pathway slows cancer cell growth 3Health News:Why so many antibodies fail to protect against HIV infection 2Health News:Smoking Still Allowed at 1 in 4 Major U.S. Airports 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: